SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences, Inc. Announces FDA Approves Veklury® for the Treatment of Non-Hospitalized Patients At High Risk for Covid-19 Disease Progression

01/21/2022 | 06:24pm EDT

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted expedited approval of a supplemental new drug application (sNDA) for Veklury® (remdesivir) for the treatment of non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19, including hospitalization or death. This approval expands the role of Veklury, which is the antiviral standard of care for the treatment of patients hospitalized with COVID-19. The expanded indication allows for Veklury to be administered in qualified outpatient settings that can administer daily intravenous (IV) infusions over three consecutive days. The FDA has also expanded the pediatric Emergency Use Authorization (EUA) of Veklury to include non-hospitalized pediatric patients younger than 12 years of age who are at high risk of disease progression. These actions by the FDA come amidst a surge in COVID-19 cases and the reduced susceptibility to several anti-SARS-CoV-2 monoclonal antibodies (mAbs) due to the Omicron variant. In contrast, Veklury targets the highly conserved viral RNA polymerase, thereby retaining activity against existing SARS-CoV-2 variants of concern. In vitro laboratory testing shows that Veklury retains activity against the Omicron variant. To date, no major genetic changes have been identified in any of the known variants of concern that would significantly alter the viral RNA polymerase targeted by Veklury. The FDA sNDA approval, pediatric EUA expansion and recently updated National Institutes of Health (NIH) Treatment Guidelines for COVID-19 that additionally recommend Veklury for treatment in non-hospitalized settings, are based on results from the PINETREE Phase 3 randomized, double-blind, placebo-controlled trial. The trial evaluated the efficacy and safety of a three-day course of Veklury for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. An analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, demonstrated that treatment with Veklury resulted in a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. In the study, no deaths were observed in either arm by Day 28. The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial, with the most common treatment emergent adverse events (=5%) in patients taking Veklury being nausea and headache. In the United States, Veklury is indicated for the treatment of COVID-19 in adults and pediatric patients (12 years of age and older and weighing at least 40 kg) who are either hospitalized or not hospitalized and are at high risk for progression to severe COVID-19, including hospitalization or death. Veklury is additionally authorized for these uses under the EUA for pediatric patients weighing 3.5 kg to less than 40 kg or pediatric patients less than 12 years of age weighing at least 3.5 kg. Veklury is contraindicated in patients who are allergic to Veklury or any of its components; please see below for additional Important Safety Information for Veklury. Under the expanded indication for Veklury, non-hospitalized adult and pediatric patients (12 years of age and older and weighing at least 40 kg) with confirmed SARS-CoV-2 infection who are at high risk for COVID-19 disease progression can be treated with a recommended treatment duration of three days to help prevent hospitalization. For hospitalized patients not on mechanical ventilation and/or ECMO, a 5-day course of treatment is recommended, with the option to extend to a total of 10-days as needed. Critically ill patients who require mechanical ventilation and/or ECMO should receive a 10-day course of treatment.

© S&P Capital IQ 2022
All news about GILEAD SCIENCES, INC.
05/19Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Progr..
05/19Junshi's COVID-19 Drug Candidate Shows Positive Results in Small Trial; Shares Jump Nea..
05/18China Junshi's potential COVID drug shows promise in small trial
05/17Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Car..
05/17Gilead Sciences, Inc. - FDA Lifts Clinical Hold on Investigational Lenacapavir for the ..
05/17WALL STREET STOCK EXCHANGE : Finding the tipping point
05/17ANALYST RECOMMENDATIONS : AMD, CarMax, Gilead, J.B. Hunt, Vodafone...
05/17Piper Sandler Adjusts Gilead Sciences' Price Target to $69 From $73, Maintains Neutral ..
05/16Gilead Sciences Says FDA Lifts Hold on Investigational Lenacapavir to Treat HIV
05/16FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention..
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 24 579 M - -
Net income 2022 4 227 M - -
Net Debt 2022 16 479 M - -
P/E ratio 2022 18,6x
Yield 2022 4,56%
Capitalization 80 075 M 80 075 M -
EV / Sales 2022 3,93x
EV / Sales 2023 3,82x
Nbr of Employees 14 400
Free-Float 99,9%
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 63,84 $
Average target price 70,07 $
Spread / Average Target 9,75%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-12.08%80 075
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612
GENMAB A/S-17.26%20 205